bimekizumab
ucb pharmaceuticals
['spondylitis', 'bimekizumab']
phase 2b: sustained efficacy of bimekizumab (anti il-17 a+f) in active ankylosing spondylitis over 3 years #acr22 #acrambassador 
Tweeting anything #Rheum #COVID-19
MD | PhD | Rheumatology #RheumTwitter